Login to Your Account

Clinic Roundup

Tuesday, October 25, 2011
PharmaGap Inc., of Ottawa, said it has chosen ovarian cancer as its target for clinical development of GAP-107B8. The company expects to apply for the first Phase I trial by the end of next year. GAP-107B8, a peptide that has been shown to be highly cytotoxic to numerous cancer types, was being considered for bladder and ovarian cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription